ArticleAdvanced biotechnology2026
Design and validation of a ribosome display library for synthetic nanobody selection.
Article in Advanced biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Single-domain antibodies (nanobodies) are compact, highly engineerable binding scaffolds widely used in structural biology, biotechnology, and therapeutics. When combined with the Legobody toolkit, they enable high-resolution cryo-electron microscopy (cryo-EM) analysis of small membrane proteins. Ribosome display is a powerful method for generating synthetic nanobodies (sybodies) with exceptionally high library diversity. However, existing sybody libraries are incompatible with the Legobody system, necessitating additional subcloning steps that reduce throughput and limit efficiency. Here, we report the rational design of a new ribosome-display-compatible nanobody library, termed S1.0, engineered for intrinsic compatibility with the Legobody platform through modifications in the C-terminal region. Compared to a benchmark sybody library, S1.0 features increased randomization in the complementarity-determining regions CDR1 and CDR3, while exhibiting reduced variability in CDR2. Selection against calmodulin demonstrated comparable efficiency to the benchmark library. Moreover, selection against thermostable green fluorescent protein (TGP) yielded multiple high-affinity sybodies, with nanomolar dissociation constants validated by size-exclusion chromatography and biolayer interferometry. Importantly, the selected sybodies are directly compatible with the Legobody system without requiring further engineering or subcloning. The S1.0 library represents a valuable resource for nanobody discovery and, in particular, provides an efficient route for generating Legobody-compatible binders suitable for structural studies of challenging small proteins by cryo-EM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.